Core Viewpoint - The company, Qianxin Biotechnology-B (02509.HK), announced that its subsidiary, Jiangsu Saifusi Biotechnology Co., Ltd., successfully passed the EU Qualified Person (QP) audit, achieving compliance with EU GMP standards [1] Group 1: Audit and Compliance - The audit was conducted by a senior QP over a three-day period, reviewing Saifusi's quality management system, advanced facilities, and professional technical team [1] - The audit team recognized the high standards of Saifusi's quality management system and confirmed that both hardware and software management meet EU GMP requirements [1] - Passing the QP audit provides a strong proof of compliance with international GMP standards, which is a prerequisite for products entering the EU market [1] Group 2: Strategic Implications - The successful QP certification marks an important milestone in the company's strategy for international expansion and product innovation [1] - This achievement lays a solid foundation for the company's future innovative products to enter global markets [1]

Core Viewpoint - The company’s subsidiary, Jiangsu Saifusi Biotechnology Co., Ltd., successfully passed the Qualified Person (QP) audit, achieving compliance with EU GMP standards, which is crucial for its international market strategy [1] Group 1: Audit and Compliance - The QP audit was conducted over three days by a senior QP, who reviewed the quality management system and production capabilities of Saifusi [1] - The audit team recognized Saifusi's high standards in quality management, advanced facilities, and professional technical team, confirming compliance with EU GMP requirements [1] - A compliance statement issued by the QP serves as a strong proof of the company's adherence to international GMP standards, essential for entering the EU market [1] Group 2: Strategic Importance - Passing the QP audit is a significant milestone for the company's product export strategy and global expansion plans [1] - This achievement lays a solid foundation for the company's future innovative products to enter international markets [1]

Financial Performance - The company reported a revenue of ¥528,042,409.63 for the first half of 2025, a decrease of 16.38% compared to ¥631,461,882.24 in the same period last year [8] - The net profit attributable to shareholders was -¥775,820.00, reflecting a decline of 155.31% year-on-year [3] - Operating costs decreased by 17.55% to ¥441,091,432.86 [8] - Research and development expenses increased by 16.40% to ¥20,173,329.07 [8] Market Strategy - The company aims to enhance its core competitiveness through industry integration and improving its main business operations [4][9] - Focus on expanding overseas markets as a key growth driver [5][9] - Plans to establish three major platforms: medical products, medical services, and healthcare industry [5] Challenges and Responses - The decline in revenue is attributed to reduced engineering income and increased interest payments on convertible bonds [3][8] - The company is addressing slow domestic business growth and delayed receivables by intensifying international market expansion and improving accounts receivable collection [9] Future Outlook - The Egyptian medical consumables production base is expected to commence operations in Q4 2025 [5] - The management emphasizes the importance of maintaining a strong business foundation to achieve sustainable returns for investors [4][9]